Protocols
ALLIANCE-ALCHEMIST-A151216 Phase N/A OPEN TO ACCRUAL
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
AZ-D9078C00001-PACIFIC-9 Phase III OPEN TO ACCRUAL
A Phase III, Double-Blind, Placebo-Controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients with Locally Advanced (Stage III), Unresectable Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
ECOG-ALCHEMIST-E4512 Phase III OPEN TO ACCRUAL
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
NRG-GY022 Phase I OPEN TO ACCRUAL
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
TAIHO-TAS6417-201 Phase II OPEN TO ACCRUAL
An Open-Label, Phase 2b, Global Multi-Center Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertions and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations